Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 605,887
  • Shares Outstanding, K 78,789
  • Annual Sales, $ 43,470 K
  • Annual Income, $ -17,930 K
  • EBIT $ 104 M
  • EBITDA $ 104 M
  • 60-Month Beta 1.39
  • Price/Sales 2.59
  • Price/Cash Flow N/A
  • Price/Book 1.59

Options Overview Details

View History
  • Implied Volatility 76.92% (+6.69%)
  • Historical Volatility 126.29%
  • IV Percentile 47%
  • IV Rank 27.80%
  • IV High 165.02% on 04/04/25
  • IV Low 42.99% on 08/15/25
  • Expected Move (DTE 9) 0.51 (6.76%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 155
  • Volume Avg (30-Day) 2,383
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 72,707
  • Open Int (30-Day) 65,522
  • Expected Range 7.03 to 8.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.86
  • Number of Estimates 2
  • High Estimate 0.88
  • Low Estimate 0.84
  • Prior Year 0.22
  • Growth Rate Est. (year over year) +290.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.55 +14.81%
on 01/20/26
8.53 -11.84%
on 02/02/26
-0.11 (-1.44%)
since 01/09/26
3-Month
6.55 +14.81%
on 01/20/26
13.02 -42.24%
on 12/30/25
-3.67 (-32.80%)
since 11/11/25
52-Week
5.60 +34.29%
on 04/07/25
17.43 -56.86%
on 06/23/25
-2.53 (-25.17%)
since 02/11/25

Most Recent Stories

More News
CorMedix Therapeutics Announces Share Repurchase Program

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.39 (-3.90%)
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.39 (-3.90%)
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

EVMN : 24.49 (-15.64%)
ATAI : 3.81 (-1.04%)
CRMD : 7.39 (-3.90%)
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential...

CRMD : 7.39 (-3.90%)
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.39 (-3.90%)
CorMedix Therapeutics Announces Leadership and Board Updates

BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.39 (-3.90%)
CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77...

CRMD : 7.39 (-3.90%)
Why CorMedix Could be the Biopharma Name to Watch Early in 2026

CorMedix is a promising biopharma firm in the catheter lock solution space. Continued success for its top products could fuel significant growth into 2026.

CRMD : 7.39 (-3.90%)
MarketBeat’s Top 5 Rated Small-Cap Stocks

Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment.

ATAI : 3.81 (-1.04%)
TRVI : 10.59 (-5.87%)
CRMD : 7.39 (-3.90%)
TREE : 43.12 (-5.95%)
MNMD : 15.02 (+1.01%)
IWM : 262.78 (-1.27%)
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.39 (-3.90%)

Business Summary

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed...

See More

Key Turning Points

3rd Resistance Point 8.20
2nd Resistance Point 8.02
1st Resistance Point 7.86
Last Price 7.40
1st Support Level 7.52
2nd Support Level 7.34
3rd Support Level 7.18

See More

52-Week High 17.43
Fibonacci 61.8% 12.91
Fibonacci 50% 11.52
Fibonacci 38.2% 10.12
Last Price 7.40
52-Week Low 5.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar